ES2094287T3 - Composicion para inducir anergia humoral contra un inmunogeno. - Google Patents

Composicion para inducir anergia humoral contra un inmunogeno.

Info

Publication number
ES2094287T3
ES2094287T3 ES92301036T ES92301036T ES2094287T3 ES 2094287 T3 ES2094287 T3 ES 2094287T3 ES 92301036 T ES92301036 T ES 92301036T ES 92301036 T ES92301036 T ES 92301036T ES 2094287 T3 ES2094287 T3 ES 2094287T3
Authority
ES
Spain
Prior art keywords
immunogen
composition
induce humoral
humoral anergy
immunogens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92301036T
Other languages
English (en)
Inventor
Paul Arlyn Barstad
Gilbert Michael Iverson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Pharmaceutical Co
Original Assignee
La Jolla Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Pharmaceutical Co filed Critical La Jolla Pharmaceutical Co
Application granted granted Critical
Publication of ES2094287T3 publication Critical patent/ES2094287T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Fats And Perfumes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE DESCRIBEN CONJUGADAS DE POLIMEROS INMUNOGENICOS ESTABLES Y ANALOGOS DE INMUNOGENES QUE POSEEN LA CAPACIDAD ESPECIFICA DE ENLACE DE CELULAS B DEL INMUNOGEN PERO CARECEN DE EPITOPES DE CELULA T Y QUE, CUANDO SE INTRODUCEN EN INDIVIDUOS, INDUCEN ENERGIA HUMORAL AL INMUNOGEN. DE ACUERDO CON ESTO, ESTOS CONJUGADOS SON UTILES PARA EL TRATAMIENTO DE PATOLOGIAS MEDIANTE ANTICUERPOS QUE SON CAUSADAS POR INMUNOGENES EXTERIORES O PROPIOS.
ES92301036T 1991-02-08 1992-02-07 Composicion para inducir anergia humoral contra un inmunogeno. Expired - Lifetime ES2094287T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/652,648 US5268454A (en) 1991-02-08 1991-02-08 Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier

Publications (1)

Publication Number Publication Date
ES2094287T3 true ES2094287T3 (es) 1997-01-16

Family

ID=24617613

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92301036T Expired - Lifetime ES2094287T3 (es) 1991-02-08 1992-02-07 Composicion para inducir anergia humoral contra un inmunogeno.

Country Status (13)

Country Link
US (5) US5268454A (es)
EP (1) EP0498658B1 (es)
JP (1) JP2544873B2 (es)
KR (1) KR100234678B1 (es)
AT (1) ATE142109T1 (es)
AU (1) AU646157B2 (es)
CA (1) CA2076648C (es)
DE (1) DE69213272T2 (es)
DK (1) DK0498658T3 (es)
ES (1) ES2094287T3 (es)
GR (1) GR3021809T3 (es)
IE (1) IE920419A1 (es)
WO (1) WO1992013558A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
AU3423293A (en) * 1991-12-19 1993-07-19 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
DE4302012C1 (de) * 1993-01-26 1994-07-21 Serosearch Gmbh Entwicklung Un Immunologischer Test
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US5874409A (en) * 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US6410775B1 (en) 1995-06-07 2002-06-25 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5817752A (en) * 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
EP0954531A1 (en) * 1996-06-06 1999-11-10 Lajolla Pharmaceutical Company aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
US6936249B1 (en) * 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
CA2326618A1 (en) * 1998-04-15 1999-10-21 Baxter International Inc. Inhibition of xenoreactive antibodies
EP1073459A4 (en) * 1998-04-27 2005-01-19 Biocrystal Ltd COMPOSITIONS AND METHODS OF TOLERATING IN IMMUNOMOPLEX-MEDIATED ILLNESS
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
DE69928995T2 (de) * 1998-06-22 2006-09-07 Affymetrix, Inc., Santa Clara Reagenz und Verfahren zu fester Phase Synthese
US6399578B1 (en) * 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US20010010818A1 (en) * 1998-12-09 2001-08-02 Engle Steven B. Methods and formulations for reducing circulating antibodies
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
CA2376057A1 (en) * 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
MXPA02005236A (es) * 1999-11-28 2004-03-19 Jolla Pharma Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos.
AU2001268228A1 (en) 2000-06-08 2001-12-17 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
AU2001296305B2 (en) 2000-09-26 2007-12-06 Duke University RNA aptamers and methods for identifying the same
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
CN1511041A (zh) * 2001-05-17 2004-07-07 ������ҩ�����޹�˾ 利用抑制cd21的药剂治疗抗体介导的病变的方法
PT2070939E (pt) * 2001-05-25 2014-06-09 Univ Duke Moduladores de agentes farmacológicos
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
US7105135B2 (en) * 2001-10-16 2006-09-12 Lockheed Martin Corporation System and method for large scale detection of hazardous materials in the mail or in other objects
AU2003303524A1 (en) * 2002-12-27 2004-07-29 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
EP1613263A4 (en) * 2003-01-31 2007-11-28 Pathologica Llc MONITORING AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
WO2004089422A2 (en) * 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals
AU2004227852B2 (en) * 2003-03-31 2010-01-14 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
DE602004009818T2 (de) * 2003-11-05 2008-09-18 Intercell Ag Zusammensetzungen, die von melittin abgeleitet sind und peptide enthalten, und verfahren zur potenzierung von immunreaktionen gegen target-antigene
PL1745062T3 (pl) 2004-04-22 2014-10-31 Regado Biosciences Inc Ulepszone modulatory czynników krzepnięcia
ITPD20040159A1 (it) * 2004-06-21 2004-09-21 Univ Degli Studi Trieste Derivati bifunzionali del polietilenglicole loro preparazione e uso.
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
EP2057998A1 (en) * 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-CONTAINING PSA COMPOSITIONS, METHODS OF ISOLATION AND METHODS OF USING SAME
US10857177B2 (en) 2015-08-19 2020-12-08 President And Fellows Of Harvard College Lipidated PSA compositions and methods
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US10864279B2 (en) * 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
EP3715375A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of pre-eclampsia
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715376A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of myasthenia gravis
AU2021347581A1 (en) 2020-09-23 2023-05-18 Ablevia Biotech Gmbh Compound for the prevention or treatment of autoantibody-mediated conditions
EP4216990A1 (en) 2020-09-23 2023-08-02 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
MX2023003375A (es) 2020-09-23 2023-03-31 Ablevia Biotech Gmbh Compuesto para aumentar la eficacia de la terapia de sustitucion del factor viii.
AU2021347583A1 (en) 2020-09-23 2023-05-25 Ablevia Biotech Gmbh Compound for increasing efficacy of viral vectors
JP2023543444A (ja) 2020-09-24 2023-10-16 アブレヴィア バイオテック ゲーエムベーハー 重症筋無力症の予防又は治療のための化合物
WO2023180502A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US107389A (en) * 1870-09-13 Improved hat and cap-bracket
US2002A (en) * 1841-03-12 Tor and planter for plowing
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US162953A (en) * 1875-05-04 Improvement in fire-alarm telegraphs
US26856A (en) * 1860-01-17 Btjoying ships
US4351A (en) * 1846-01-07 Straw-cutter
US2005A (en) * 1841-03-16 Improvement in the manner of constructing molds for casting butt-hinges
US103990A (en) * 1870-06-07 Improvement in liquid-meters
US82400A (en) * 1868-09-22 Improvement in kossfflg-maoeines
US31635A (en) * 1861-03-05 Straw-cutter
US4388441A (en) * 1977-02-03 1983-06-14 Scripps Clinic & Research Foundation Induction of immunological tolerance
US4191668A (en) * 1977-02-03 1980-03-04 Scripps Clinic And Research Foundation Induction of immunological tolerance
US4220565A (en) * 1979-01-18 1980-09-02 Scripps Clinic & Research Foundation Immunochemical conjugates: method and composition
US4430260A (en) * 1979-02-27 1984-02-07 Lee Weng Y Penicillin-polyvinyl alcohol conjugate and process of preparation
JPS56145222A (en) * 1980-04-28 1981-11-11 Toshiyuki Hamaoka Improved antibody and its preparation
GB2102825A (en) 1981-07-31 1983-02-09 Ici Plc Polymer-modified polyols
US5126131A (en) * 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
CH668554A5 (de) * 1984-04-09 1989-01-13 Sandoz Ag Liposomen welche polypeptide mit interleukin-2-aktivitaet enthalten sowie verfahren zu ihrer herstellung.
GB8411550D0 (en) * 1984-05-04 1984-06-13 Stylo Matchmakers Int Injection moulding apparatus
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4950713A (en) * 1986-05-30 1990-08-21 La Jolla Pharmaceutical Company Conjugates of D-glutamic acid: D-lysine copolymer and certain biochemicals
US5017648A (en) * 1986-05-30 1991-05-21 La Jolla Pharmaceutical Company D-GL conjugate therapy
US4950469A (en) * 1986-05-30 1990-08-21 La Jolla Pharmaceutical Company D-GL conjugate therapy
US4886782A (en) * 1987-02-26 1989-12-12 The United States Of America As Represented By The Department Of Health And Human Services Malarial immunogen
JPS6468398A (en) * 1987-09-08 1989-03-14 Agency Ind Science Techn Monoclonal anti-idiotype antibody and hybridoma and use thereof
USD321129S (en) 1988-06-28 1991-10-29 Henkel Kommanditgesellschaft Auf Aktien Container for dispensing liquid detergent or similar article
US5102663A (en) * 1988-10-18 1992-04-07 Sloan-Kettering Instutute For Cancer Research Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3
DE473721T1 (de) * 1989-05-25 1993-04-29 Sloan-Kettering Institute For Cancer Research, New York, N.Y., Us Antiidiotypischer antikoerper, der eine immunantwort gegen ein glykosphingolipid induziert und seine verwendung.
JP2704779B2 (ja) * 1989-12-15 1998-01-26 本田技研工業株式会社 加速度検知装置
US5162515A (en) 1990-01-16 1992-11-10 La Jolla Pharmaceutical Company Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
DE69127470T2 (de) * 1990-03-02 1998-02-19 Autoimmune Inc Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
US5177188A (en) * 1990-12-03 1993-01-05 The Scripps Research Institute Methods and compositions for diagnosing chronic immune thrombocytopenic purpura
CA2098281A1 (en) * 1990-12-17 1992-06-18 Howard M. Dintzis Suppression of immune responses of oligomeric forms of antigen of controlled chemistry
ATE129900T1 (de) * 1990-12-19 1995-11-15 Schering Corp Anwendung von il-4 zur steigerung der immunantwort auf immunogene in impfstoffen.
AU664184B2 (en) 1991-07-15 1995-11-09 La Jolla Pharmaceutical Company Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides
US5736146A (en) * 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
US5718352A (en) 1994-11-22 1998-02-17 Aluminum Company Of America Threaded aluminum cans and methods of manufacture
US5778723A (en) 1992-07-31 1998-07-14 Aluminum Company Of America Method and apparatus for necking a metal container and resultant container
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6410775B1 (en) 1995-06-07 2002-06-25 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6138847A (en) 1999-02-25 2000-10-31 Johnson; Russell Joe Disposable non-reusable baby bottle
USD424444S (en) 1999-05-27 2000-05-09 Mott's Inc. Combined bottle and cap
WO2006003368A2 (en) 2004-07-01 2006-01-12 The University Court Of The University Of Edinburgh Improved c-element and logic reduction and completion detection circuits

Also Published As

Publication number Publication date
US5268454A (en) 1993-12-07
GR3021809T3 (en) 1997-02-28
WO1992013558A1 (en) 1992-08-20
US20050170436A1 (en) 2005-08-04
US6060056A (en) 2000-05-09
KR100234678B1 (ko) 1999-12-15
US7138244B2 (en) 2006-11-21
JP2544873B2 (ja) 1996-10-16
ATE142109T1 (de) 1996-09-15
JPH05508421A (ja) 1993-11-25
IE920419A1 (en) 1992-08-12
US20050031635A1 (en) 2005-02-10
CA2076648A1 (en) 1992-08-09
EP0498658B1 (en) 1996-09-04
US7208156B2 (en) 2007-04-24
DE69213272T2 (de) 1997-01-30
US20030103990A1 (en) 2003-06-05
US7163683B2 (en) 2007-01-16
EP0498658A2 (en) 1992-08-12
AU1411892A (en) 1992-09-07
EP0498658A3 (en) 1993-05-12
DK0498658T3 (es) 1997-02-17
CA2076648C (en) 1999-08-17
AU646157B2 (en) 1994-02-10
DE69213272D1 (de) 1996-10-10

Similar Documents

Publication Publication Date Title
ES2094287T3 (es) Composicion para inducir anergia humoral contra un inmunogeno.
DE69637481D1 (de) Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
PT1075259E (pt) Novos analogos gordos para o tratamento de diabetes
ES520985A0 (es) Procedimiento para la preparacion de nuevos 6,11-dihidrodibenzo (b,e)-tiepin-11-n-alcohilnorescopin-eteres cuaternarios.
DE3761307D1 (de) Herstellung von fibraten.
ATE69817T1 (de) Tetraoxodiazabicyclo-(3,3,1)-nonane.
UY24654A1 (es) Composición de vacuna contra la malaria
ES523966A0 (es) Procedimiento para preparar granulos de metasilicato de sodio
DK148183A (da) Fremgangsmaade til fremstilling af imidazolylphenyl-tetrahydropyridaziner
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
DK0786004T3 (da) Kloning, ekspression og karakterisering af en hidtil ukendt form af phosphatidylinositol-3-kinase
DK0787124T3 (da) Fremgangsmåde til fremstilling af substituerede 3-aminobenzonitriler
BR9710849A (pt) Vacina contendo uma peróxi-redoxina e/ou uma beta-tubulina.
ATE30719T1 (de) Imino-2-pyrrolidine, verfahren zu ihrer herstellung und ihre therapeutische verwendung.
DK1082962T3 (da) Anvendelse af 2-hydroxy-4-trifluormethylbenzoesyrederivater som inhibitorer af aktiveringen af de nukleare transskriptionsfaktorer NF-(K)B
EA200100188A1 (ru) Способы и композиции для лечения болезни гастроэзофагеального рефлюкса
DK0536197T3 (da) Ren, krystallinsk form af rifapentine
PL283722A1 (en) Method for manufacturing phenylhydrazones
CA2277724A1 (en) A composition for inducing humoral anergy to an immunogen
DK0702565T3 (da) Immuniserende sammensætning baseret på Helicobacter pylori katalase
DE60008378D1 (de) Ledergerben
ES2069539T3 (es) Emulsiones estables en agua de fluidos de hidruro de silicona.
ES535757A0 (es) Procedimiento para la obtencion de alcoxiaril-alcanoles
BR9103804A (pt) Composicao clara,aquosa,estavel a armazenamento para cabelos humanos
DK1093451T3 (da) Faststofsammensætninger egnede til oral indgivelse indeholdende ikke-hygroskopiske salte af L-carnitin og alkanoyl-L-carnitiner

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 498658

Country of ref document: ES